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determinants of poet Ml cardiovascular drug use including nationality. Sig-
nificant differences exiatad between patient groups treated within the United
States (US) and other nations (NUS) (Europe, Canada&Australia). The US
group had a greater proportion of females, hypertensive (HTN), diabetica
and patients with prior bypass surgery (all p c 0.002). No differeneas wera
notad in age, time to treatment, recurrent ischemia or ra-infarction (all p >
0.05). The last ESVI before hospital discharge was significantly smaller in
US patienta compared to NUS (p -=0.0001). Multivariable analysis identified
determinants of long term cardiovascular drug use listad below according to
rank. (p value).
ACE Calcium Blwcker Bets Blocker Vasodilators
tESVl (0.0001) HTN (0.0001) NUS (0.0001) NUS
HTN (0.0001) us (0.0002) NoCHF (0.0001) Smoker (0.09)
CHF (0.0001) JESVI (0.02) HTN (0.002) Female (0,01)
NUS (0.0001) NoCHF (0.03) Age <75 (0.002) -
Diabetee (0.001) Smoker (0.03) ~Lipids (0.05) -
Female (0.01) - $ESVI (0.009) -
Conclusions.’ 1). Long term post Ml drug use is in pari dependent on
nation specific practice patterns after correction for specific drug indications.
2). US patients are less likely to receive ACE inhibitors or bate blockers than
NUS patients post Ml. The etiology of these differences is unknown. The
‘global community” is not yet a madicsl reality regarding post Ml medical
therapy.
m1078127 T WavaChangeaAftarReperfuesdAcuteMyocardialinfarction:A Markerof infarctSiza
T. Onodera, A. Takizawa, M.-S. Kim, H. Fukita, A. Uehara, T. Urushida,
T. Yonada, S. Miyamaoto, M. Matsunaga, T. Kubota. S/rizuo/raCify M.spita/,
Shizuoka, Japan
Implication of asymptomatic pracordial T wave changes after anterior acute
myocardial infarction (AMI) were evaluated in 84 patients who receivedemer-
gent angiography with reparfusion therapy. ECG recordings were obtained
tiicea day for a week. Patients were divided into those without Twave inver-
sion after reperfusion therapy, those who showad normalization of invertad
T wave in convalescent phase of AMI and those without normalization of
invertad T wave. Left ventricular ejection fraction (LVEF), % systolic short-
ening of infarct-related segment (%SS), left ventricular end-diastolic volume
index (EDVI) and patency of the infarct-related artery were evaluated in
angiography’on admission and at 1 month of AMi.
T wave inversion was noted in 74 of 84 patients. Normalization of invertad
T wave was seen in 49 of the 74 patienta at 82 + 32 hours after onset of AMI.
T inversion(–) T normalization(+) T normalization(–)
peak CK (lUil) 6846+ 3765* 4754 &2547# 2123+ 1031
On admission
LVEF (%) 40+5” 44 +9# 55* 16
%ss -1,6+ 1.9$ 6.1 &6.9# 13.1 * 10.1
EDVI 101 * 11” 92& 16 84*2O
1 monthafter AMI
LVEF (%) 38& 9* 46* 13# 56 k 14
%ss 2.7& 5.9* 10.4+ 8,ti 19.2 + 6.6
EDVI 129 + 20” 92& 17 65& 16
Coronaty reoeclueion 2/10 (20%) 5/49 (lo%) 4/25 (16%)
*p< 0.05 veothers, #p < 0.05va T nOrmalizstiOn(–)
Thus, absence of T wave invereion after reperfusion therapy was as-
sociated with the largest infarction. Infarction waa larger in patients with
normalization of invertad T wave than in thoae without normalization. T wave
changes were not associated with coronary raoeelusiort.UprightTwave may
l“
be a sign of left ventricular remodeling or profounder myoeardial damage.
D 1078-128 lathe ECGAdequateto idantifyPatientsWithLeftCircumflexOccluaioninAcuteCoronary
Syndromes?
P.B.Amsterdam, G.E. Hafley, R.A. Barrington, C.B. Granger, E.J. Topol,
o R.M. Califf for the GUSTO-llb Investigators. Duke University Msdica/
,
Centec Durham, NC, USA
Studies of acute coronary syndromes (ACS) have shown that STelevation is
highly specific, but less sensitive, for total coronaty oeelusions,particularly of
l the left circumflex (LCX). To further investigate the ECG characteristics and
o outcomes of acute LCXoeelusions, weetudiad patients inthe GUSTO-llbtrial
(of heperin vs. desirudin in ACS) with enzymatic evidence of Ml at enrollment
and the LCX identified astheculpritartery ateardiaceetheterization. Of these,
250 had evidence of LCX occlusion based on ST elevation at presentation,
.
and 1S0 had no ST elevation but LCX occlusion based on 100% stenosis
and/or TIMI c 2 flow. Thus, 41.9% of patients with LCX occlusion and Ml had
no ST elevation. Outcomes for these patiente are shown (table).
n Death at 30 deye, Peek CK-MS, Killipz Ill, LytiesJIQPTCA,
n n (“A) lull n (OA) n (“/.)
ST+ 250 1 (0.4)” not 12 (4.6) 224 (90)
No’ST? 160 8 i4.4i* 71t 15 i6.3i 33 (;6.3)
*p= 0.004;t p = 0.0003
Conclusion: Absence of ST elevation in Ml due to LCX occlusion is
ebmmon. Mortality was significantly higherat30 days in the non-ST-elevation
group, perhape because fewer got reperfusion therapy despite occluded
culprit arteries. More sensitive, noninvasive ways to identify LCX occlusion
(than the 12-lead ECG) should be developad to determine whether these
patients, if identified early, would benefit from repatiusion therapy.
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D1079110 A 8eiectiveUeeofTissuePlaeminogenActivator
and8treptokinasefor AcuteMyocardiai
infarctioniaMoreCoat-affectiveThanthe
ExclusiveUeeofTissuePlasminogenActivator
R. Lorenzoni, G. Fattore, G. Gensini. Inst. of Cwdio/ogy, Universifyof
F/orenceand Bocconi Univerei~ Milan, Italy
Thrombolysis in acute myocardial infarction (AMI) with tissue plasminogen
activator (tPA) is eoet-effactive in respect to the use of streptokineee (SK).
Aim of this refxxl istotest the cost-effectiveness of aseleetive use of SKand
tPA for the treatment of AMI. Methods: We testad two alternative protocols.
Protoco/ A: tPA in patients agad c 75 yeare, SK in patients aged z 75
yeare. Protoco/B:tPA in patienta with anterior AMI, SK in patients with other
AMI. The mats for the two thrombolytic strategies are those repotted for
GUSTO trial: tPA 2.216 and SK 270 US $/treatment; no additional coats
were Computed.Thirly-day mortality ratee and distribution in subgroups (in
brackets after each subgroup) are those repotied in the GUSTO trial: tPA
6.3% and SK 7.3% for the general population; tPA 4.4% in patients agad <
75 yeare (88Y.), SK 20.6% in patients agad ? 75 years (12%); tPA 8.6% in
patients with anterior AMI (39%), SK 5.3% in patients with other AMI (61%).
Resu/te.’Data are for 1.000 patients treated and rests are expressad in US
$. The exclusive use of SK costs 270.000 with 73 deaths. Costs, deaths,
and costs for each extra life saved with the exclusive use of tPA and the
use of protocol A and B in respect to the exclusive use of SK, are shown in
tabie.
costs Deaths Cost/lifesaved
tPA 2,216,000 63 t94,600
ProtocolA 1,962,480 64 190,276
ProtocolB i.02s.e40 65 e4.s67
Therefore, the cost of each extra life saved (2 life saved every 1.000
patients treatad) with the exclusive use of tPA inetead of the use of protccol
B would be 593.530. Conclusions: The use of tPA in anterior AMI and SK in
other AMI could be more cost-effective than the exclusive uae of tPA.
W1’ThrombinGeneration~urin9Thr m~oiYaiawi~~
rt-PAandConjunctiveTherapyWithr-Hirudinin
PatientsWithAcuteMyocardiaiInfarction
U. Zeymer, M. Mateblowski, K.-L. Neuhaus. SWffische K/iniken Kaase/,
Germany
Thrombolytic therapy is known to induce not only Iysis of thrombi but also
proeoagulant effects. Thrombin is one of the most important factors invoivad
in the pethogenesis of acute corona~ syndromes. We determined thrombin
generation in 17 patients with acute myoeardial infarction before, during and
after thrombolyeis with front-loaded rt-PA (100 m@O rein) and conjunctive
therapy with raeombinant hirudin (HBW 023; bolus of 0.4 mg/kg, infusion of
0.15 mg/k@h over 46 houm). Pro-thrombin fragment 1.2 (F1.2), thrombin-
antithrombin Ill complex (TAT) and free r-hirudin plaama levels (Hir) were
determined at baseline (before), during (30 and 80 rein) and after (4 and 24
h) thrombolysis. Mean values+ SD are shown in the table.
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before 30 min 60 mln 4h 24 h
F1.2 (nmol/1) 3 & 4.4 11.1 * 6 8.3 * 7 6.9 & 6 1.5 * 1
TAT (@) 21 l 17 10* 7 17* 22 22• 22 14* 9
Hir (rig/ml) <32 1545 1441 1529 13.54
*I + 361 +410 & 329 * 330
APPT was constantly prolonged between 2-3 times control during the
treatment period.
Conclusion: Thrombolydc therapy with I’I-R4 in Patients with aCUte mY-
ocerdial infarction Is associated with an increase in thrombin generation
which ia not suppressed by therapeutic doses of the specific thrombin in-
hibitor r-hirudin, while circulating thrombin seems to be effectively inhibited
by r-hirudin.
EmEl Successful Revascularizetion by DirectCoronary Angloplasty Reducad the Expression
of Polym-orphon-uclearLeukocyte Adhesion
Molacules of Patients with Acute Myocardial
Infarction
Y. Sakai, T. Inoue, H. Hatano, K. Hoshi, 1.Yaguchi, K. Takayanagi,
T. Hayashi, S. Morooka. Depaflrnerrt of Carcfio@ry.Koehig8ya Hospital,
L70kkyoUn/vers/fySck3010fMedicine, S8iIerna, Japan
In acute myocardial infarction, it was well known that the early revaacular-
ization aavad the ischemic myocardium but caused the reperfusion injuriea.
Direct percutaneous trensluminal coronary angioplaefy (pTCA) is the most
desirable therapy to save the iechemic myocardium, but it is unknown why
direct PTCA is better than intracoronaty thrombolysis (lCT) to acute my-
ocardlal infarction. So we atudiad the difference in inflammatory activation
between direct PTCAand ICT using leukocyte adhesion molecules including
LFA-I (CDlldCD18), Mac-1 (CDIIWCD18), L-selwtin (CD62L) and sia-
Iyl Lewisx (SLX) in acute myocardial infarction. Twenty patients with acute
myocerdial infarction were treated with successful revascularizstion within 6
hours after the onset. In ICT group (12 patients), the levels of CD18, CDlla,
CDllb, CD62Land SLX increased immediately after revascularization. In di-
rect PTCA group, the levels were significantly lower than those of ICT group
(CD18: 47 + 6 VS 149 + 23, P <0.05, CDllb: 658 +90 VS 901 + 96, P <
0.05, CD62L: 32 + 7 vs 50 l 15, P < 0.05). Especially, 8 patients of ICT
group hadventricular arrhythmia at rsparfusion and showad a significant cor-
relation with CDllb level. In conclusion, direct PTCA reducedthe expression
of polymorphonuclear leukocyte adhesion molecules at the revascularization
of acute myocardial infarction and dacreaaad tha reperfusion injuries more
than intrscoronary thrombolysis in acute myocardial infarction.
m1079113 Early ACE Inhibitor Therapy Enhances theBenefits of Late Coronary Artery Reparfusion on
Infarct Expansion
P.Sahgal, E.J. Brown, Jr., L. Tkaczevski, R. Mir, N. Muia, Jr., LA. Alhaddad.
Nassau Counfyfdedicai Center, East Meadow, NY USA, Bronx Lebanon
Hospital Centec Bronx, NY USA
Reperfusion 8 hours after experimental rat myocardial infarction will limit
infarct expenaion. Our purpose was to examine the effects and mechanism
of earfy ACE Inhibitor therapy on infarct expanaion when combined with late
raperfusion. Rate underwent 8 houre of coronary artery occlusion followed
by permanent raperfusion. The enalapril group raceivad enalapril (0.1 mg/Kg
IV) 1 hour after coronary occlusion followed by enalapril (1.0 + 2 mg/Kg)
daily in drinking water. A control group received placebo. Two weeka after
myooardiel infarction, the hearts wera arrestad and fixad at a constant end
diaatolic pressure, then sectioned for morphometric analysis. Hearf sections
were stained with H&E for histological analysis. Viable ialets of myocytes
within the scar (Viable Myccytes) were quantitatad and call diameters were
measured. Results follow as mean + SEM.
Enalapril(n = 10) Control(n =9) P
ExpansionIndex 1.17 * 0,12 1.57 i 0.12 <0.05
infarctThickneaa(mm) 0.93 * 0.07 0.76 + 0.04 <0.05
Vlsble Myccytes (“A) 11.6 + 3.70 9.40 + 2.50 N.S.
Viable MyocyteS-DlametSr(pm) 11,1 * 1.50 8.80 i 1.30 <0.01
Non InfarctMyocytea-Diamster (pm) 11.3 l2.2 8.40 + 1.80 <0.01
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Sulfonylurea Drug USCIs Associated With
Increased Early Mortality During Diract Coronary
Anglopleety For Acute tiyocardisl Infarction -
Among Diabetic Patients
K.N. Garratt, N. Hassinger, D.E. Grill, A. Terzic, S.S. Srivatee, D.R. Holmes,
Jr.. Mayo C/inic, RochesteCMN, USA
Whether sulfonylurea therapy, which blocks cyfoprotective ATP-sensitive
potassium channels, impedes cardioprotective mechanisms during ischemic
events remains controversial. Therefore, we reviewad dare for 188 diabetic
pts with acute myocardial infarction treated with direct angioplasty at Mayo
Clinic to determine the effect of sulfonylurea drug use on clinical outcome.
There wera 115 (81%) males, mean + SD age 65 + 12 yre; 39 (21%)
presented with heart failure, 67 (36%) were taking an oral sulfonylurea hypo-
glycemicdrug, Angioplasfy was successful (Iuminal improvement > 40%, no
death, new infarction of bypass surgety) in 148 (79%) pts. Logistic modeling
[OR = odds ratio, Cl = upper and lower 95% confidence intervals] identified
sulfonylurea drug use (OR= 2.5, Cl = 1.1-5.6, P =0.03) in addition to lettven-
tricularejacfion fraction < 40% (OR =7, Cl = 1.6-31.2, P= O.01),prior bypass
surgery (OR = 3.6, Cl = 1.3-9.9, P = 0.01), age (OR= 1.05, Cl = 1.006-1.09,
P = 0.02), and heati failure (OR= 2.3, Cl= 1-5.4, P = 0.06) as correlates of
increased in-hospital mortality. Elevated glycosylated hemoglobin, gender,
hypertension, and hyperoholesteroiemia were not associated with Increased
mottslify risk. Survivors were followed for a mean + SD of 3.7 + 2.4 yra. Cox
proportional hazards modeling found heart failure (relative riak (RR) = 3.5,
P = 0.0006), female gender (RR= 0.5, P = 0.03), prior bypass surgery (RR
= 3, P = 0.03) and hypertension (RR = 0.4, P = 0.04) but not aulfonylurea
drug use to be associated with late morfalify. ConchAons: Among diabetic
pfs undergoing direct angioplasty for acute myocardial Infarction, oral sul-
fonylurea drug use appears to confer an increased risk of early mortality
roughly equivalent to that conferred by heari failure. Late survival was not
influenced by sulfonylurea therapy. Interactions between sulfonylurea drugs
and ATP-sensitive potassium channels participating in myocardial protection
to prolonged ischemia are postulated to contribute to an increesad earty
mortality risk.
LQEuE.1‘nc~a=dp’ate’etAgg~gationDuringcorona~
Thrombolysls as a Predictor for Early and Lsta
Reocclusion
T.K. Nordt, M. Moaer,K. Peter, B. Kohler, C. Bode. Med. Un/versiMtsk/inik
Heide/Lrerg,Germany
Reocclusion after initially auccesaful thrombolysia is detrimental to the long-
tanmoutmme after acute myocardial infarction (AMI). Besides angiogrsphic
criteria, no clinical variables could be identified as predictor for reocclusion.
To evaluate hemoeteaeologic criteria as potential riak determinants 31 pa-
tients with AMI were monitored by thrombin antithrombin complexea (TAT,
representing plasmatic hemoatasis), platelet aggregation (PA, representing
callular hemostesis), and plasminOgenactivator inhibitor type 1 (PAI-1, rep-
resenting endogenous fibrinolysis) at O, 1, 2, and 12 h after initiation of
thrombolysis as well as at discharge. Raocclusion was defined as rein-
farcfion or angiographioelly confirmed ailent reocclusion and occurred in 5
patienta within 10 d and in 8 patients within 1 y. TAT levels were lower in
patients with raocclusion veraus those without (9.9 + 2.5 va. 22.9 + 4.4
n~ml at 2 h, 6.5 + 1.4 vs. 11.2 + 1.3 ngfml at 12 h, meane + SEM, p <
0.05). The concentration and activity of PAI-1 did not differ in both patient
groupe. However, both alope and maximum of PA (induced by 2 #M ADP)
were augmented with reoccluaion [slope: 39.4 + 0.8 vs. 32.5 + 1.5 at 2 h
(p < 0.001), 42.6 + 1.2 va. 36.6 + 1.7 at 12 h (p -= 0.01)]. Results were
independent of the thrombolytic agent uaad (alteplase or reteplase). A PA
slope at 2 h higher than the average slope at O h (37.0) could be identified
as beat predictor for earfy (within 10 d, p <0.01, sensitivity 100%, specificity
69%) and late reocclusion (within 1y, p c 0.01, 66% and 74%, respectively).
Thua, increased PA under coronary thrombolysis appears to be aaeociated
with early and late raocclusion. Thia marker could be useful in identifying
patients who may profit from more aggressive interventional or antiplatelet
strategies.
In conclusion, earty ACE Inhibitor therapy enhances the benefits of late
coronary reperfusion on infarct expansion. These benefits maybe related to
hyperfrophy of viable myocytes within the infarcted as well as non-infarcted
zone.
